» Articles » PMID: 8418271

Myocardial Uptake of Metaiodobenzylguanidine in Patients with Left Ventricular Hypertrophy Secondary to Valvular Aortic Stenosis

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 1993 Jan 1
PMID 8418271
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The time course of myocardial uptake of metaiodobenzylguanidine ([123I]MIBG) was studied in 26 patients: seven control subjects (Group 1) and 13 patients with left ventricular hypertrophy secondary to valvular aortic stenosis. Seven of these had received no treatment (Group 2) and six were receiving amiodarone or digoxin (Group 3); six heart transplant recipients were investigated for extra neuronal myocardial uptake of [123I]MIBG (Group 4). The index of myocardial [123I]MIBG uptake was lower in Groups 2 and 3 than in Group 1 (Group 2: 1.42 +/- 0.07, p < 0.001; Group 3: amiodarone, 1.30 +/- 0.10, p < 0.05; digoxin, 1.22 +/- 0.06, p < 0.01; Group I: 1.83 +/- 0.18) and lower in Group 3 than in Group 2. Patients of Group 4 showed a much lower mean index of myocardial [123I]MIBG uptake than the control group (1.07 +/- 0.08, p < 0.001).

In Conclusion: 1. Patients with left ventricular hypertrophy secondary to valvular aortic stenosis were found to have lower myocardial [123I]MIBG activity and rapid washout than the control subjects. 2. Amiodarone and digoxin partially inhibited myocardial [123I] MIBG uptake. 3. Extra neuronal myocardial uptake of [123I]MIBG in humans only accounts for 13% of the total cardiac activity.

Citing Articles

Left ventricular hypertrophy as a predictor of cardiovascular outcomes after transcatheter aortic valve replacement.

Ito N, Zen K, Takahara M, Tani R, Nakamura S, Fujimoto T ESC Heart Fail. 2023; 10(2):1336-1346.

PMID: 36725669 PMC: 10053161. DOI: 10.1002/ehf2.14305.


Cardiac sympathetic dysfunction in left ventricular hypertrophy caused by arterial hypertension and degenerative aortic stenosis.

Liga R, Gimelli A, De Carlo M, Marzullo P, Pedrinelli R, Petronio A J Nucl Cardiol. 2020; 29(1):337-347.

PMID: 32613476 DOI: 10.1007/s12350-020-02250-w.


Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature.

Jacobson A, Travin M J Nucl Cardiol. 2015; 22(5):980-93.

PMID: 25975946 DOI: 10.1007/s12350-015-0170-z.


Age-related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I-123 metaiodobenzylguanidine imaging.

Chen W, Botvinick E, Alavi A, Zhang Y, Yang S, Perini R J Nucl Cardiol. 2008; 15(1):73-9.

PMID: 18242482 DOI: 10.1016/j.nuclcard.2007.09.027.


Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added 123I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity.

Verberne H, Busemann Sokole E, van Moerkerken A, Deeterink J, Ensing G, Stabin M Eur J Nucl Med Mol Imaging. 2008; 35(4):798-807.

PMID: 18183394 PMC: 2668584. DOI: 10.1007/s00259-007-0668-y.